There was more terrible economic news today as core durable goods orders fell for the 21st straight month which is the longest decline outside of a recession. Business spending which is calculated as new orders non-defense, ex-aircraft fell 1.2% month over month. The jobless claims was once again great, but one has to question how long this can last given the decline in other indicators.
Twitter Inc (NYSE:TWTR) reported Q3 EPS of $0.13 which beat estimates by 4 cents. Revenue of $616 million was up 8.2% which beat estimates by $10.16 million. Advertising revenue was $545 million which was up 6%. Data licensing and other revenue was $71 million which was up 26%. U.S. revenue was $374 million which was up 1%. International revenue as $242 million which was up 21%. The company is reducing its global workforce by 9%.
Bristol-Myers Squibb Co (NYSE:BMY) reported Q3 EPS of $0.77 which beat estimates by 12 cents. Revenues were $4.92 billion which was up 20.9% year over year beat $130 million. The following is the sales results of key products: Opdivo up 201.6%, Eliquis up 89.7%, Orencia up 18.2%, Sprycel up 14.8%, Hep C Franchise down 5.7%, Baraclude down 4.4%, Yervoy up 18.8%, Sustiva Franchise down 17.4%, Reyataz down 11.9%. A $3 billion stock repurchase plan was authorized.
F5 Networks, Inc. (NASDAQ:FFIV) reported Q4 EPS of $2.11 which beat estimates 17 cents. Revenue was $525.35 million which was up 4.8% and beat estimates by $5.03 million. The CEO John McAdam stated “We believe there are several emerging market conditions that are driving an increased appeal of our products with our customers. These include the ability to orchestrate SSL traffic flows, provision our proxy based security solutions to deploy a consistent security stack across on-premise, off-premise and public cloud infrastructures, and customers moving workloads to public and private cloud architectures. We believe these trends, combined with our new product offerings will drive our business forward in fiscal 2017 and beyond.”